Bcr-Abl/Lyn inhibitor (AB Science)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug NameBcr-Abl/Lyn inhibitor (AB Science)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionBcr-Abl tyrosine kinase inhibitorsTyrosine-protein kinase Lyn inhibitors
TargetsTyrosine-protein kinase LynBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAb Science
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAb Science
Active IndicationsN/A
Inactive IndicationsLeukemia, Myelogenous, Chronic

Other Information

ATC CodeN/A
Related LinksN/A